drug delivery

Latest Headlines

Latest Headlines

EyeGate ekes out a tiny IPO to fund its R&D efforts

Massachusetts' EyeGate Pharmaceuticals picked up $10 million in an IPO do-over, raising cash to support its sole clinical candidate.

Eli Lilly reveals drug delivery, device innovation center to be based in Cambridge

Eli Lilly will open a new drug delivery and device innovation center in Cambridge, MA. Medical devices aren't a focus for the pharma now--but it noted that more than half of its current pipeline candidates are biologics that require injection. It expects to double its revenues from device-enabled products by 2020 and is looking to have a hand in that arena.

Langer team offers up a hydrogel drug delivery vehicle at MIT

Researchers in the lab of MIT's Robert Langer have created a hydrogel that's designed to be much better than current technologies in getting drugs into patients and straight to where they are targeted.

Biotech upstart enGene preps first trial for next-gen 'gene pill' tech

Montreal-based enGene has lined up $11.5 million in venture financing to put its next-gen approach to an inflammatory bowel disease treatment through its first clinical test.

Medtronic reaches another milestone in developing its artificial pancreas

Medical device giant Medtronic said it reached another milestone in developing an artificial pancreas with the completion of global evaluations of its new insulin delivery system.

Bind shares dented after heralding cancer drug data from a mixed PhII

Bind Therapeutics believes its lead nanoparticle treatment can make a difference for a subgroup of lung cancer patients, pointing to some positive results from an otherwise mixed mid-stage trial as it prepares for further study.

Biogen scores fresh MS advance with blockbuster Plegridy OK

Billing it as the most important new innovation in the interferon drug class in a decade, Biogen Idec nailed down the FDA's approval of Plegridy, a new multiple sclerosis drug that patients can easily inject themselves with once every two weeks.

AcelRx shares plunge after FDA rejects its pain drug/device system

Shares of AcelRx took a painful 30% plunge on Monday morning as investors got a chance to respond to the biotech's announcement late Friday night that the FDA had rejected its application for Zalviso, its sufentanil sublingual microtablet drug/device system for fighting pain.

Fresh off Phase III success, Otonomy shoots for an $86M IPO

San Diego biotech Otonomy isn't biding its time, filing to go public in an $86.3 million IPO just three days after unveiling positive Phase III results for its lead drug.

InVentiv signs on to market 3-D printed drugs

Aprecia has an MIT-licensed method of 3-D printing pills and a plan to hit the market with easy-to-take formulations of top-selling medicines. To get there, the biotech has tapped CRO inVentiv Health, which is on hand to lend its commercialization expertise.